Nebivolol improves obesity-induced vascular remodelling by suppressing NLRP3 activation.
Nebivolol is a novel β-adrenergic receptor (β-AR) blocker with anti-inflammatory and antioxidant properties. The NLRP3 inflammasome plays a pivotal role in the pathogenesis of obesity-induced vascular dysfunction. Our study aimed to explore the effect of nebivolol on the NLRP3 inflammasome and vascular remodelling in diet-induced obese rats. Eight-week-old Sprague-Dawley male rats were fed with either a standard chow diet (ND) or a high-fat diet (HFD) for 8 weeks. Next, the obese rats were subdivided into three groups as follows: 1) HFD control group; 2) HFD with low doses of nebivolol (5 mg /kg/d); and 3) HFD with high doses of nebivolol (10 mg/kg/d). A four-week treatment with nebivolol improved acetylcholine-induced vascular relaxation in accordance with an increased aortic endothelial nitric oxide synthase. Nebivolol enhanced the levels of phase II detoxifying enzymes, including superoxide dismutase and catalase. In parallel, nebivolol attenuated NLRP3 inflammasome activation and suppressed autophagy. These effects were associated with an increased β3-AR level. Moreover, nebivolol treatment significantly increased of AMP-activated protein kinase activity and decreased of phosphorylation of the mammalian target of rapamycin. These results demonstrated that nebivolol improves obesity-induced vascular remodelling by attenuating NLRP3 inflammasome activation and restoring the antioxidant defence.